Trial Profile
Phase II Randomised Clinical Trial Evaluating an EGFR Tyrosine Kinase Inhibitor (EGFR-TKI) Versus an EGFR-TKI Combined With an Anti-oestrogen Treatment (Fulvestrant) in Women With Advanced Stage Non-squamous Lung Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Mar 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Fulvestrant (Primary) ; Fulvestrant (Primary) ; Gefitinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms LADIE
- 06 Jan 2021 Status changed from active, no longer recruiting to completed.
- 07 Feb 2020 Planned End Date changed from 1 Dec 2019 to 1 May 2020.
- 30 Aug 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.